(Q79256704)

English

A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy

scientific article published on 12 October 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

phase II clinical trial

1 reference

based on heuristic

inferred from title

ovarian carcinoma

1 reference

based on heuristic

inferred from title

author name string

Whitney A Spannuth

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Charles A Leath

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Warner K Huh

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Mack N Barnes

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Susan A Davidson

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Larry C Kilgore

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Edward E Partridge

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

J Maxwell Austin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Ronald D Alvarez

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

12 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

104

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

591-595

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17045635%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.09.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q79256704&oldid=1506777216"